Clinical Trial Update: A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tocilizumab for moderate-to-severe rheumatoid arthritis in patients with inadequate response to or intolerance of DMARDs compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2012-04-17